CEO Om Manchanda expects planned expansion of central lab network in Kolkata and Lucknow will help Dr Lal PathLabs to sustain margins in FY17. Diagnostics space which has low penetration in India makes it a good pitch for companies like Dr Lal PathLab, ... Money Control, 2 weeks ago
Diagnostic industry is growing at 17% & we continue to see same momentum: Om Manchanda, CEO, Dr Lal PathLabs - Economic Times, 4 weeks ago
Diagnostic sector is growing at 17% & we continue to see same momentum: Om Manchanda, CEO, Dr Lal PathLabs - Economic Times, 4 weeks ago
New Delhi, Jun 26 () Diagnostic services provider Dr Lal PathLabs is looking at around 18 per cent revenue growth this fiscal year as it undertakes initiatives to expand number of tests offered and its network across India. The company had posted a ...Times of India, 2 days ago Dr Lal PathLabs eyeing 18% growth in FY17 Moneycontrol.com, 1 day ago Dr Lal PathLabs eyeing 18 per cent growth in FY17 Economic Times, 2 days ago Dr Lal PathLabs CEO on expansion, competing with PE-backed players and more VC Circle, 2 weeks ago
Mass yoga demonstration in Chandigarh, an expected turnout of 25,000 to 30,000 people, seven points for demonstration of yoga across Delhi, and multiple events on various scales planned for the rest of the country and the world; the Ministry of ...DNA India, 2 weeks ago
Diagnostic major Thyrocare Technologies, listed at a 49 per cent premium over its initial public offering (IPO) price of Rs 446 last Monday, is trading near Rs 630. The trend is similar to the one seen with Dr Lal PathLabs, which listed a few months ...Smart Investor, 1 month ago
Thyrocare Technologies, the diagnostic major, listed at a 49% premium over its IPO price of Rs 446 last Monday and is now at Rs 630 levels. The trend is similar to the one seen with Dr Lal PathLabs which listed a few months back. Compared to the IPO ...Business Standard India, 1 month ago
on your WebpageAdd Widget >Get your members hooked!